MX2015017609A - Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer. - Google Patents

Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer.

Info

Publication number
MX2015017609A
MX2015017609A MX2015017609A MX2015017609A MX2015017609A MX 2015017609 A MX2015017609 A MX 2015017609A MX 2015017609 A MX2015017609 A MX 2015017609A MX 2015017609 A MX2015017609 A MX 2015017609A MX 2015017609 A MX2015017609 A MX 2015017609A
Authority
MX
Mexico
Prior art keywords
peptidomimetics
peptides
treatments
cancer patient
combination uses
Prior art date
Application number
MX2015017609A
Other languages
English (en)
Other versions
MX366341B (es
Inventor
Takumi Kawabe
Takuji Sato
Naoki Mine
Naoya Saito
Keiichi Sakakibara
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52141164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015017609(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Publication of MX2015017609A publication Critical patent/MX2015017609A/es
Publication of MX366341B publication Critical patent/MX366341B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención proporciona compuestos que incluyen péptidos y peptidomiméticos que se pueden usar para tratar trastornos proliferativos, tales como los asociados con células de tumores benignos y malignos. Mientras la invención no se limita a ningún mecanismo particular, los compuestos de la invención pretenden funcionar al menos parcialmente inhibiendo el punto de control del Ciclo celular G2. Entonces, los compuestos de la invención se pueden usar para inhibir solo el crecimiento celular o se puede usar en combinación con un tratamiento de daño de ácido nucleico para inhibir el crecimiento celular.
MX2015017609A 2013-06-24 2014-06-24 Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer. MX366341B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361838777P 2013-06-24 2013-06-24
PCT/IB2014/001579 WO2014207556A1 (en) 2013-06-24 2014-06-24 Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations

Publications (2)

Publication Number Publication Date
MX2015017609A true MX2015017609A (es) 2016-04-15
MX366341B MX366341B (es) 2019-07-05

Family

ID=52141164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017609A MX366341B (es) 2013-06-24 2014-06-24 Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer.

Country Status (28)

Country Link
US (1) US9221872B2 (es)
EP (1) EP3013351B1 (es)
JP (1) JP6401255B2 (es)
KR (1) KR102247493B1 (es)
CN (1) CN105324121A (es)
AU (1) AU2014300713B2 (es)
BR (1) BR112015032542A2 (es)
CA (1) CA2916136C (es)
CL (1) CL2015003704A1 (es)
CY (1) CY1122523T1 (es)
DK (1) DK3013351T3 (es)
ES (1) ES2765300T3 (es)
HK (1) HK1219905A1 (es)
HR (1) HRP20192264T1 (es)
HU (1) HUE046873T2 (es)
IL (1) IL243266B (es)
LT (1) LT3013351T (es)
MX (1) MX366341B (es)
MY (1) MY182232A (es)
PH (1) PH12015502855A1 (es)
PL (1) PL3013351T3 (es)
PT (1) PT3013351T (es)
RS (1) RS60180B1 (es)
RU (1) RU2732440C2 (es)
SG (1) SG11201510490VA (es)
SI (1) SI3013351T1 (es)
WO (1) WO2014207556A1 (es)
ZA (1) ZA201600089B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
US9822157B2 (en) 2013-03-15 2017-11-21 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
DK3143037T3 (da) 2014-05-16 2021-09-20 Protagonist Therapeutics Inc Alpha4beta7-integrin-thioether-peptidantagonister
EP3169403B1 (en) 2014-07-17 2024-02-14 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
EP3201217A4 (en) 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
TWI805542B (zh) * 2015-10-23 2023-06-21 日商坎巴斯有限公司 用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3017926C (en) 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Methods for synthesizing .alpha.4.beta.7 peptide antagonists
PL3464336T3 (pl) 2016-06-01 2022-05-16 Athira Pharma, Inc. Związki
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
US11753443B2 (en) 2018-02-08 2023-09-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CN114341161A (zh) 2019-07-10 2022-04-12 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
JP7441955B2 (ja) 2020-01-15 2024-03-01 ヤンセン バイオテツク，インコーポレーテツド インターロイキン２３受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用
MX2023005994A (es) 2020-11-20 2023-08-11 Janssen Pharmaceutica Nv Composiciones de inhibidores peptidicos del receptor de interleucina-23.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100863090B1 (ko) * 2002-01-17 2008-10-13 다케다 파머수티컬 컴패니 리미티드 항증식 활성을 지니고／지니거나 핵산 손상제 또는 처리제를 증강시키는 펩티드 및 펩티드모방체
PL212929B1 (pl) * 2002-10-31 2012-12-31 Metabasis Therapeutics Inc Pochodna cytarabiny, jej zastosowania oraz kompozycja farmaceutyczna zawierajaca ta pochodna
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
EP1648490A2 (en) * 2003-06-25 2006-04-26 Canbas Co., Ltd. Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity
CN102149725A (zh) * 2008-05-14 2011-08-10 三井有限公司 用于抑制g2细胞周期停滞和使细胞对dna损伤剂敏感的cbp501衍生制剂及基于其的方法

Also Published As

Publication number Publication date
JP6401255B2 (ja) 2018-10-10
ZA201600089B (en) 2020-02-26
PH12015502855B1 (en) 2016-04-04
DK3013351T3 (da) 2020-01-27
HRP20192264T1 (hr) 2020-03-06
RU2016101718A3 (es) 2018-03-01
JP2016522245A (ja) 2016-07-28
NZ715285A (en) 2021-09-24
IL243266A0 (en) 2016-03-31
ES2765300T3 (es) 2020-06-08
SI3013351T1 (sl) 2020-03-31
CA2916136C (en) 2022-10-18
HUE046873T2 (hu) 2020-03-30
MX366341B (es) 2019-07-05
SG11201510490VA (en) 2016-01-28
AU2014300713A1 (en) 2016-01-21
RU2016101718A (ru) 2017-07-28
HK1219905A1 (zh) 2017-04-21
LT3013351T (lt) 2020-01-10
CY1122523T1 (el) 2021-01-27
PT3013351T (pt) 2020-01-17
EP3013351B1 (en) 2019-10-30
IL243266B (en) 2019-11-28
KR20160021792A (ko) 2016-02-26
US9221872B2 (en) 2015-12-29
CA2916136A1 (en) 2014-12-31
RS60180B1 (sr) 2020-06-30
US20150056301A1 (en) 2015-02-26
PL3013351T3 (pl) 2020-05-18
CN105324121A (zh) 2016-02-10
MY182232A (en) 2021-01-18
KR102247493B1 (ko) 2021-04-30
WO2014207556A1 (en) 2014-12-31
BR112015032542A2 (pt) 2017-07-25
CL2015003704A1 (es) 2016-07-29
AU2014300713B2 (en) 2019-02-14
RU2732440C2 (ru) 2020-09-16
PH12015502855A1 (en) 2016-04-04
EP3013351A4 (en) 2017-03-01
EP3013351A1 (en) 2016-05-04

Similar Documents

Publication Publication Date Title
PH12015502855B1 (en) Peptides and petidomimetics in combination uses and treatments for cancer patient subpopulations
PH12018500869A1 (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
MX2015017485A (es) Uso de moleculas inhibidoras de semaforina-4d en combinacion con una terapia de modulacion inmune para inhibir crecimiento tumoral y metastasis.
MX2015009209A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos.
MX2015005963A (es) Inhibidores heterociclicos de glutaminasa.
MX2016004678A (es) Composiciones para el tratamiento del cancer.
MX2016013027A (es) Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX359664B (es) Tratamiento de cáncer de mama.
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
HK1223923A1 (zh) 用於治療癌症的作為 突變體抑制劑的 -或 -二氨基嘧啶化合物
MX2014011583A (es) Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
MX2019010098A (es) Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico.
NZ627480A (en) Inhibitors of iap
AU2015279834A8 (en) Use of peptides that block metadherin-SND1 interaction as treatment for cancer
EA201492187A1 (ru) Способы лечения солидных опухолей с использованием кофермента q10
MY176599A (en) Treatment of prostate cancer with tor kinase inhibitors
MX2016016507A (es) Composiciones y metodos para tratar canceres.
PH12021550035A1 (en) Combination therapy
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы
MX359337B (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
PH12016000355B1 (en) Use of xanthophylls for the treatment of cancers
UA78354U (ru) Способ лечения базально-клеточного рака кожи

Legal Events

Date Code Title Description
FG Grant or registration